14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.03 $5.16 Wednesday, 1st May 2024 BCRX stock ended at $4.57. This is 10.65% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 14.94% from a day low at $4.15 to a day high of $4.77.
90 days $4.03 $6.35
52 weeks $4.03 $9.07

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
May 03, 2023 $8.13 $9.07 $8.00 $8.29 7 327 166
May 02, 2023 $7.50 $7.55 $7.28 $7.37 3 328 437
May 01, 2023 $7.59 $7.63 $7.45 $7.51 2 846 473
Apr 28, 2023 $7.49 $7.67 $7.48 $7.61 1 845 637
Apr 27, 2023 $7.72 $7.75 $7.45 $7.53 1 912 096
Apr 26, 2023 $7.48 $7.69 $7.42 $7.62 1 942 228
Apr 25, 2023 $7.58 $7.58 $7.41 $7.49 2 062 315
Apr 24, 2023 $7.51 $7.61 $7.36 $7.61 2 772 736
Apr 21, 2023 $7.40 $7.55 $7.27 $7.52 2 594 852
Apr 20, 2023 $7.39 $7.55 $7.27 $7.38 3 213 738
Apr 19, 2023 $7.46 $7.54 $7.40 $7.49 3 267 024
Apr 18, 2023 $7.96 $7.97 $7.20 $7.50 6 892 984
Apr 17, 2023 $8.15 $8.26 $8.05 $8.07 5 541 778
Apr 14, 2023 $8.38 $8.38 $8.00 $8.07 3 674 883
Apr 13, 2023 $8.41 $8.61 $8.39 $8.41 2 995 126
Apr 12, 2023 $8.59 $8.62 $8.34 $8.34 1 371 089
Apr 11, 2023 $8.57 $8.58 $8.45 $8.50 1 635 146
Apr 10, 2023 $8.61 $8.80 $8.37 $8.52 1 862 865
Apr 06, 2023 $8.56 $8.78 $8.44 $8.68 2 672 341
Apr 05, 2023 $8.32 $8.58 $8.29 $8.53 2 371 358
Apr 04, 2023 $8.41 $8.43 $8.22 $8.30 3 001 148
Apr 03, 2023 $8.31 $8.49 $8.23 $8.37 1 935 346
Mar 31, 2023 $8.48 $8.56 $8.30 $8.34 2 753 202
Mar 30, 2023 $8.64 $8.71 $8.31 $8.39 2 042 406
Mar 29, 2023 $8.62 $8.69 $8.37 $8.56 2 567 972
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT